Status:
COMPLETED
Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension
Lead Sponsor:
University of Florida
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Mayo Clinic
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Pulmonary arterial hypertension (PAH) is fatal with right heart failure due to raised pulmonary vascular pressure. Gut dysbiosis was identified in animals with pulmonary hypertension. Deidentified hum...
Detailed Description
Stool samples will be collected from people with no, mild-moderate or severe pulmonary arterial hypertension. Bacterial DNA will be extracted from the feces and sequenced by whole genome sequencing (s...
Eligibility Criteria
Inclusion
- severe, mild-moderate or no pulmonary arterial hypertensive subjects
Exclusion
- Patients with pulmonary hypertension due to left heart disease, lung diseases and / or hypoxia, chronic thromboembolic pulmonary hypertension, and pulmonary hypertension with unclear multifactorial mechanisms.
Key Trial Info
Start Date :
June 6 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT04104490
Start Date
June 6 2015
End Date
December 31 2021
Last Update
October 27 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224
2
Universidade Federal de Ciências da Saúde de Porto Alegre
Porto Alegre, Brazil, CEP 900050-170